Enhancement of Immune Responses Elicited by Nanovaccines through a Cross-Presentation Pathway

Tissue Eng Regen Med. 2023 Jun;20(3):355-370. doi: 10.1007/s13770-023-00527-y. Epub 2023 Mar 8.

Abstract

Numerous studies have aimed to develop novel advanced vaccines, in part because traditional vaccines have been unsuccessful in preventing rapidly emerging and reemerging viral and bacterial infections. There is a need for an advanced vaccine delivery system to ensure the successful induction of humoral and cellular immune responses. In particular, the ability of nanovaccines to modulate intracellular antigen delivery by inducing exogenous antigens (loaded onto major histocompatibility complex class 1 molecules) in CD8+ T cells, the so-called cross-presentation pathway, has attracted a great deal of attention. Protection against viral and intracellular bacterial infections relies on cross-presentation. This review discusses the advantages, requirements, and preparation of nanovaccines, the cross-presentation mechanism, the several parameters affecting cross-presentation by nanovaccines, and future perspectives.

Keywords: Cross-presentation; Dendritic cell; Exogenous antigen; Nanovaccine; Protective immune response.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens / metabolism
  • CD8-Positive T-Lymphocytes / metabolism
  • Cross-Priming*
  • Vaccines* / metabolism

Substances

  • Antigens
  • Vaccines